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This report is based on 30 deaths from chronic beryllium disease (CBD) in the United Kingdom
with details of 19 autopsies. The majority were fluorescent lamp workers and machinists who
died from respiratory failure. There were no cases of lung cancer. The survival times ranged from
less than 1 to 29 years and was longest in machinists. All of the workers showed interstitial
pulmonary fibrosis with varying degrees of cystic change. The majority showed hyalinized, and a
few active sarcoid-type, granulomas. Extrathoracic granulomas, as in a U.K. sarcoid autopsy
series, were rare. A notable difference was the absence of myocardial involvement in CBD
compared to an incidence of 20% in the sarcoid autopsies. The detection of beryllium in the
criteria for diagnosis is emphasized and the cases classified as definite include 12 of 19 positive
analysis, 6 of 19, negative or unavailable analysis. The remaining case was classified as dubious
because, despite a positive analysis, granulomas were absent. The main differential diagnosis is
sarcoidosis. Environ Health Perspect 104(Suppl 5):949-951 (1996)
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Introduction
Detailed autopsy studies of chronic beryl-
lium disease (CBD) are few and very
incomplete. In the majority, histology was
only available from the lungs or hilar
glands. Previous reports have often been
duplicated and autopsy findings often have
not been distinguished from biopsies.
The present report is based on 30 deaths
from the United Kingdom Beryllium Case
Registry (1), which now totals 69 proven
and probable cases including seven cases
with skin lesions only. The United
Kingdom Registry includes all cases of
beryllium and suspected beryllium disease
referred to or known to the author that
occurred in the United Kingdom between
1945 and 1993. Entry to the registry is
dependent on proven beryllium exposure
and clinical-radiological features. Details will
be presented of 19 autopsies, 2 previously
published (2,3) and 5 published during life
(4-9). Due to the paucity ofmaterial, the
present findings are combined with the few
relevant reports from other countries,
mainly the United States (10-15), Spain
(16), Germany (17), and Finland (18).
The pathology of the lungs and hilar
glands will be described, together with the
distribution of extrathoracic granulomas,
the latter compared to findings in the
United Kingdom series of 30 sarcoid
autopsies (19).
Finally, the criteria for diagnosis of
CBD in the series will be delineated along
with the differential diagnosis from
sarcoidosis (1).
Mortality Study
The majority of the 30 deaths were in
fluorescent lamp workers: 13 were involved
in manufacturing, experimental develop-
ment, and disposal; 9 were metal machin-
ists working with pure beryllium metal and
mainly beryllium alloys; the remaining 8
included 2 millers, 2 foundry workers,
1 ceramic worker, 1 air sampler, 1 ore
crusher, and 1 carpenter in a beryllium
machine shop.
The majority (25 of30) died from res-
piratory failure and 5 from unrelated
causes: coronary thrombosis, 1; cirrhosis,
1; perforated duodenal ulcer, 1; carcinoma
of the prostate, 1; and carcinoma of the
stomach, 1. The survival times, onset of
disease to death, ranged from 2 to 29 years
and, though not statistically significant,
machinists were the longest survivors
(Table 1). There was no relationship
between survival time, length of exposure,
and lag period before developing disease
(data not shown). There are no data for
level ofexposure, but the longest survivor,
29 years, was a metal machinist with high
tissue levels during life and extensive skin,
lymphatic, and lung disease (20).
Pulmonary Pathology
As expected from the long survival time,
all patients showed end-stage interstitial
fibrosis with varying degrees ofcystic, hon-
eycomb change (Figure 1). None showed
any active interstitial inflammation. The
fibrosis tended to be most marked in the
upper zones, although it could affect the
whole lung and, in less severe cases, the
peripheral zones. All were associated with
pleural thickening.
Four cases showed intercavity mycetomas
(aspergillus infection), an expected compli-
cation oflong standing disease and steroid
therapy. In five cases, palpable nodular
scars, up to 2 cm in diameter, were present.
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Table 1. Survival time of patients previously exposed to beryllium.
Survival time, years
Occupation, no. cases 0-5 6-10 11-15 16-20 21-25 26-30 Not known
Fluorescent lamp workers, 13 2 3 2 0 2 2 2
Machinists, 9 - 2 1 2 2 1 1
Others, 7
Ceramic worker, 1 1
Ore crusher, 1 1
Air sampler, 1 1
Foundry workers, 2 1 1
Millers, 2 1 1
2 2 1 1 1 1
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Figure 1. Large section: lung of fluorescent lamp
worker showing cystic changes.
The large nodules consisted ofsolid masses
of hyalinized fibrous tissue with scanty
remnants of granulomas and Schaumann
bodies. With one exception all showed
widespread, mainly hyalinized sarcoid-type
and, in six cases, persisting active cellular
granulomas (Figure 2). None showed
epithelial atypia, tumorlets, or cancer.
Schaumann bodies were found in the
majority, 15 of 19 cases, and were very
numerous in 3 (Figure 3). They are a use-
ful marker of preexisting granulomas in
otherwise nondiagnostic nodular scars, but
are not specific for CBD since they are
equally common in sarcoidosis (21).
Hilar Lymph Nodes
Histology was available in 10 of 19 cases.
As in the lung, the majority showed hyalin-
ized granulomas. In 3 cases, the glands were
completely replaced by confluent hyaline
scarringwith scattered Schaumann bodies.
Extrathoracic Granulomas
In the present and previous reports (Table
2) information is scanty; in the majority of
cases, histology was only available from the
main center of interest-lungs and hilar
lymph nodes. With one exception, involv-
ing the brain (15) the lesions were asymp-
tomatic with isolated granulomas in the
various organs. Lymph-node granulomas
have been found in cervical and mesenteric
glands. Granulomas were absent in the
bone marrow of 5 patients, thyroid of 3,
testis of2, GI tract of2, and prostate of 1.
In a comparison of the presence of
granulomas in CBD and sarcoid autopsies
Figure 2. Active and hyalinizing granulomas.
Figure 3. Schaumann bodies in hyalinized scartissue.
(19) (Table 3) the most notable difference
is the absence ofmyocardial granulomas in
CBD (zero of seven cases) compared to a
high incidence in sarcoidosis (8 of 30).
This reflects the well-recognized cardiac
involvement, sometimes causing sudden
death, in sarcoidosis (29) but never
recorded in CBD. The liver appears to be
equally affected but, again, as in CBD, this
organ is usually asymptomatic. Splenic
granulomas are more common in sarcoido-
sis, while renal granulomas are uncommon
in both. This suggests that the reported
Table 2. Autopsy results: extra-thoracic granulomas.
Disease: cases found/number examined
CBD Sarcoidosis
Present Jones Williams
Organ series Others 1992
Liver 1/6 5/13 16/30
Lymph nodes 1/3 3/5
Spleen 0/3 2/11 11/30




Myocardium 0/6 0/7 8/30
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Table 3. Autopsy comparison of CBD/sarcoidosis.
CBD, % Sarcoidosis, %
Patient parameters (n=19) (n=30)
History of beryllium 100 0
exposure
Myocardial granuloma 0/7 27
Positive beryllium analysis 92 0





high incidence (10%) (23) of renal calculi
in CBD, as in sarcoidosis, is unrelated to
the presence ofgranulomas.
Criteria for Diagnosis
It is now generally recognized (1) that the
criteria for diagnosis includes history of
exposure, consistent clinical or radiological
features, presence of granulomas, tissue
analysis, and evidence ofhypersensitivity.
In the author's view, positive tissue
analysis is considered essential. Results of
atomic absorption spectrometry, and the
qualitative laser microprobe mass spec-
trometry, LAMMS, (24) were positive in
12 of 13 cases tested. The one patient who
tested negative in this test had a positive
patch test.
The Role ofSensitivity Tests. [Two
hundred fifty-one patients are recently
being extensively investigated (26) with
the suggestion of identifying preclinical
disease. In the present series the beryllium
lymphocyte transformation (BeLT) test
was positive in two offour patients and the
patch test in five ofseven, in total seven of
nine (70%). Beryllium was detected in
both BeLT negative cases.
In this series, all five criteria were satis-
fied in six patients and the first four criteria
in a further six patients. A total of 12
patients are thus classified as definite cases
of CBD. Six other patients met the first
three criteria were met but they lacked
confirmatory analysis. The BeLT test was
negative in one test, not available in the
remainder. One had a positive patch test.
These six cases are classified as probable,
because, despite a history of exposure,
sarcoidosis cannot be excluded.
The remaining case is problematic and
classified as dubious. The patient, a beryl-
lium air sampler for 12 years and without
granulomas, had a positive LAMMS analy-
sis and a negative BeLT test. He suffered
from long-standing seropositive rheuma-
toid arthritis. He exemplifies the truism
that any single criterion above is insuffi-
cient for diagnosis with the possibility of
low, areactive exposure.
Finally, the main pathological differen-
tial diagnosis is sarcoidosis (27). Because
the gross and microscopic features are
identical, the real distinction requires the
detection of beryllium in the granulomas
and/or scars.
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